Dimethyl fumarate for multiple sclerosis

Bibliography

• Schweckendiek W. Treatment of psoriasis vulgaris. Med Monatsschr 1959;13:103-4
   PubMedGoogle Scholar
• Schweckendiek W. Behandlung von Psoriasis vulgaris mit lipoidloslichen Fumarsaureverbindungen. Medizin heute 1966;15:219-20
   Google Scholar
• Altmeyer P, Hartwig R, Matthes U. Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients. Hautarzt 1996;47:190-6
   PubMed Web of Science ®Google Scholar
• Altmeyer PJ, Matthes U, Pawlak F, Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994;30:977-81
   PubMed Web of Science ®Google Scholar
• Bayard W, Hunziker T, Krebs A, Peroral long-term treatment of psoriasis using fumaric acid derivatives. Hautarzt 1987;38:279-85
   PubMed Web of Science ®Google Scholar
• Carboni I, De Felice C, De Simoni I, Fumaric acid esters in the treatment of psoriasis: an Italian experience. J Dermatolog Treat 2004;15:23-6
   PubMedGoogle Scholar
• Gollnick H, Altmeyer P, Kaufmann R, Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris. Dermatology 2002;205:46-53
   PubMed Web of Science ®Google Scholar
• Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J Am Acad Dermatol 1992;27:769-71
   PubMed Web of Science ®Google Scholar
• Litjens NH, Nibbering PH, Barrois AJ, Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol 2003;148:444-51
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 1998;138:456-60
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol 1999;141:424-9
   PubMed Web of Science ®Google Scholar
• Nast A, Kopp I, Augustin M, German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res 2007;299:111-38
   PubMed Web of Science ®Google Scholar
• Nieboer C, De Hoop D, van Loenen AC, Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis. J Am Acad Dermatol 1989;20:601-8
   PubMed Web of Science ®Google Scholar
• Nieboer C, De Hoop D, Langendijk PN, Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica 1990;181:33-7
   PubMedGoogle Scholar
• Nugteren-Huying WM, van der Schroeff JG, Hermans J, Suurmond D. Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 1990;22:311-12
   PubMed Web of Science ®Google Scholar
• Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003;149:363-9
   PubMed Web of Science ®Google Scholar
• Thio B, van der Schroeff JG, Nugteren-Huying WM, Vermeer BJ. Long term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm) in psoriasis. J Eur Acad Dermatol Venereol 1995;4:35-40
   Google Scholar
• No authors listed. BG12: BG00012, BG12/Oral Fumarate, FAG-201, second-generation fumarate derivative–Fumapharm/Biogen Idec. Drugs R D 2005;6:229-30
   PubMedGoogle Scholar
• Werdenberg D, Joshi R, Wolffram S, Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos 2003;24:259-73
   PubMed Web of Science ®Google Scholar
• Litjens NH, Burggraaf J, van Strijen E, Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol 2004;58:429-32
   PubMed Web of Science ®Google Scholar
• Rostami YM, Mrowietz U. Fumaric acid esters. Clin Dermatol 2008;26:522-6
   PubMed Web of Science ®Google Scholar
• Gerdes S, Shakery K, Mrowietz U. Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells. Br J Dermatol 2007;156:838-42
   PubMed Web of Science ®Google Scholar
• Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene 2006;25:6758-80
   PubMed Web of Science ®Google Scholar
• Liang Y, Zhou Y, Shen P. NF-kappaB and its regulation on the immune system. Cell Mol Immunol 2004;1:343-50
   PubMed Web of Science ®Google Scholar
• Loewe R, Pillinger M, de Martin R, Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappaB-dependent manner. J Invest Dermatol 2001;117:1363-8
   PubMed Web of Science ®Google Scholar
• Loewe R, Holnthoner W, Groger M, Dimethylfumarate inhibits TNF-induced nuclear entry of NF-κB/p65 in human endothelial cells. J Immunol 2002;168:4781-7
   PubMed Web of Science ®Google Scholar
• Lukashev M, Zeng W, Ryan S, Activation of Nrf2 and modulation of disease progression in EAE models by BG00012 (dimethyl fumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotective modalities. Mult Scler 2007;13(Suppl 2):149
   PubMed Web of Science ®Google Scholar
• Rescigno M, Martino M, Sutherland CL, Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med 1998;188:2175-80
   PubMed Web of Science ®Google Scholar
• Vandermeeren M, Janssens S, Wouters H, Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappaB1, but not RelA in normal human dermal fibroblast cells. J Invest Dermatol 2001;116:124-30
   PubMed Web of Science ®Google Scholar
• Yamazoe Y, Tsubaki M, Matsuoka H, Dimethylfumarate inhibits tumor cell invasion and metastasis by suppressing the expression and activities of matrix metalloproteinases in melanoma cells. Cell Biol Int 2009;33:1087-94
   PubMed Web of Science ®Google Scholar
• Calabrese V, Ravagna A, Colombrita C, Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2. J Neurosci Res 2005;79:509-21
   PubMed Web of Science ®Google Scholar
• Li J, Johnson D, Calkins M, Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells. Toxicol Sci 2005;83:313-28
   PubMed Web of Science ®Google Scholar
• Hubbs AF, Benkovic SA, Miller DB, Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2. Am J Pathol 2007;170:2068-76
   PubMed Web of Science ®Google Scholar
• Satoh T, Okamato SI, Cui J, Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophillic phase II inducers. Proc Natl Acad Sci USA 2006;103:768-73
   PubMed Web of Science ®Google Scholar
• Vargas MR, Pehar M, Cassina P, Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: consequences for motor neuron survival. J Biol Chem 2005;280:25571-9
   PubMed Web of Science ®Google Scholar
• Zhao C, Zawadzka M, Roulois AJ, Promoting remyelination in multiple sclerosis by endogenous adult neural stem/precursor cells: defining cellular targets. J Neurol Sci 2008;265:12-6
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med 2005;11:43-8
   PubMed Web of Science ®Google Scholar
• Schrempf W, Ziemssen T. Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun Rev 2007;6:469-75
   PubMed Web of Science ®Google Scholar
• Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998;51:682-9
   PubMed Web of Science ®Google Scholar
• Asadullah K, Schmid H, Friedrich M, Influence of monomethylfumarate on monocytic cytokine formation – explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res 1997;289:623-30
   PubMed Web of Science ®Google Scholar
• De Jong R, Bezemer AC, Zomerdijk TP, Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996;26:2067-74
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Li H, Schmitz A, Improvement of herpetic stromal keratitis with fumaric acid derivate is associated with systemic induction of T helper 2 cytokines. Clin Exp Immunol 2005;142:180-7
   PubMed Web of Science ®Google Scholar
• Litjens NH, Rademaker M, Ravensbergen B, Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur J Immunol 2004;34:565-75
   PubMed Web of Science ®Google Scholar
• Moed H, Stoof TJ, Boorsma DM, Identification of anti-inflammatory drugs according to their capacity to suppress type-1 and type-2 T cell profiles. Clin Exp Allergy 2004;34:1868-75
   PubMed Web of Science ®Google Scholar
• Stoof TJ, Flier J, Sampat S, The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol 2001;144:1114-20
   PubMed Web of Science ®Google Scholar
• Hoxtermann S, Nuchel C, Altmeyer P. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis. Dermatology 1998;196:223-30
   PubMed Web of Science ®Google Scholar
• Treumer F, Zhu K, Glaser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003;121:1383-8
   PubMed Web of Science ®Google Scholar
• Bureau F, Vanderplasschen A, Jaspar F, Constitutive nuclear factor-kappaB activity preserves homeostasis of quiescent mature lymphocytes and granulocytes by controlling the expression of distinct Bcl-2 family proteins. Blood 2002;99:3683-91
   PubMed Web of Science ®Google Scholar
• Hildeman DA, Zhu Y, Mitchell TC, Molecular mechanisms of activated T cell death in vivo. Curr Opin Immunol 2002;14:354-9
   PubMed Web of Science ®Google Scholar
• Kolenko V, Bloom T, Rayman P, Inhibition of NF-kappaB activity in human T lymphocytes induces caspase-dependent apoptosis without detectable activation of caspase-1 and -3. J Immunol 1999;163:590-8
   PubMed Web of Science ®Google Scholar
• Zhu K, Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol 2001;116:203-8
   PubMed Web of Science ®Google Scholar
• Cannella B, Cross AH, Raine CS. Adhesion-related molecules in the central nervous system. Upregulation correlates with inflammatory cell influx during relapsing experimental autoimmune encephalomyelitis. Lab Invest 1991;65:23-31
   PubMed Web of Science ®Google Scholar
• Lossinsky AS, Badmajew V, Robson JA, Sites of egress of inflammatory cells and horseradish peroxidase transport across the blood-brain barrier in a murine model of chronic relapsing experimental allergic encephalomyelitis. Acta Neuropathol 1989;78:359-71
   PubMed Web of Science ®Google Scholar
• Vandermeeren M, Janssens S, Borgers M, Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun 1997;234:19-23
   PubMed Web of Science ®Google Scholar
• Ockenfels HM, Schultewolter T, Ockenfels G, The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 1998;139:390-5
   PubMed Web of Science ®Google Scholar
• Sebok B, Bonnekoh B, Vetter R, The antipsoriatic dimethyl-fumarate suppresses interferon-gamma -induced ICAM-1 and HLA-DR expression on hyperproliferative keratinocytes. Quantification by a culture plate-directed APAAP-ELISA technique. Eur J Dermatol 1998;8:29-32
   PubMed Web of Science ®Google Scholar
• Zhu K, Mrowietz U. Enhancement of antibacterial superoxide-anion generation in human monocytes by fumaric acid esters. Arch Dermatol Res 2005;297:170-6
   PubMed Web of Science ®Google Scholar
• Wierinckx A, Breve J, Mercier D, Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J Neuroimmunol 2005;166:132-43
   PubMed Web of Science ®Google Scholar
• Bal-Price A, Brown GC. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci 2001;21:6480-91
   PubMed Web of Science ®Google Scholar
• Bo L, Dawson TM, Wesselingh S, Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 1994;36:778-86
   PubMed Web of Science ®Google Scholar
• Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002;1:232-41
   PubMed Web of Science ®Google Scholar
• van der Goes A, Brouwer J, Hoekstra K, Reactive oxygen species are required for the phagocytosis of myelin by macrophages. J Neuroimmunol 1998;92:67-75
   PubMed Web of Science ®Google Scholar
• SantaCruz KS, Yazlovitskaya E, Collins J, Regional NAD(P)H:quinone oxidoreductase activity in Alzheimer's disease. Neurobiol Aging 2004;25:63-9
   PubMed Web of Science ®Google Scholar
• van Muiswinkel FL, de Vos RA, Bol JG, Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging 2004;25:1253-62
   PubMed Web of Science ®Google Scholar
• Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006;129:1953-71
   PubMed Web of Science ®Google Scholar
• Mix E, Meyer-Rienecker H, Zettl UK. Animal models of multiple sclerosis for the development and validation of novel therapies – potential and limitations. J Neurol 2008;255(Suppl 6):7-14
   PubMed Web of Science ®Google Scholar
• Storch MK, Stefferl A, Brehm U, Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998;8:681-94
   PubMed Web of Science ®Google Scholar
• Schilling S, Goelz S, Linker R, Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 2006;145:101-7
   PubMed Web of Science ®Google Scholar
• Bista P, Luo Y, Mi S, Dimethyl fumarate (BG00012) inhibits astrocyte and microglial activation. Mult Scler 2009;15(2):S132 [abstract P457]
   Google Scholar
• Ryan S, Mi S, Hahm K, Dimethyl fumarate (BG00012) inhibits astrogliosis in rodent EAE Models. Neurology 2009;72(11):379 [abstract P08.054]
   Web of Science ®Google Scholar
• Schimrigk S, Brune N, Hellwig K, Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 2006;13:604-10
   PubMed Web of Science ®Google Scholar
• Kappos L, Gold R, Miller DH, Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;372:1463-72
   PubMed Web of Science ®Google Scholar
• van Walderveen MA, Barkhof F, Pouwels PJ, Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 1999;46:79-87
   PubMed Web of Science ®Google Scholar
• Mac Manus D, Miller D, Kappos L, The effect of BG00012 on conversion of gadolinium-enhancing lesions to T1-hypointense lesions. Mult Scler 2008;14:163; P459
   Google Scholar
• Gold R, Arnold D, Kappos L, Baseline characteristics of patients in the DEFINE trial: a randomized, multicenter, double-blind, placebo-controlled, phase 3 study of BG-12 in relapsing-remitting multiple sclerosis. Neurology 2010;74(2):A546, P06.149
   Google Scholar
• Fox R, Miller D, Phillips T, Baseline characteristics of patients enrolled in a randomized, multicenter, placebo-controlled and active comparator trial evaluating efficacy and safety of BG-12 in relapsing-remitting multiple sclerosis: the CONFIRM Trial. Neurology 2010;74(2):A549, P06.158
   Google Scholar